Labcorp completes the acquisition of select assets of BioReference Health's oncology and clinical testing services businesses in the United States.
The acquisition includes certain customer accounts and other operating assets, with a total purchase price of up to $225 million.
This strategic move aims to expand access to Labcorp's high-quality laboratory services and strengthen the company's position in oncology.
Acquisition Completion
Labcorp finalized the acquisition of BioReference Health's oncology and clinical testing assets for up to $225 million, enhancing its laboratory services portfolio.
Strategic Advantages
The transaction deepens Labcorp's commitment to advancing cancer care and reinforces its leadership in oncology testing services.
Financial Details
The purchase price includes $192.5 million paid at closing and up to $32.5 million as an earnout based on performance metrics.
- Labcorp's acquisition bolsters its presence in the oncology testing market, providing patients and physicians with enhanced testing capabilities.
- The addition of BioReference Health's assets aligns with Labcorp's goal to improve healthcare outcomes and expand its diagnostic offerings.
Labcorp's acquisition of BioReference Health's oncology and clinical testing services assets signifies a significant step in advancing cancer care and strengthening its position in the healthcare industry.